Brivaracetam

• CAT Number: R020192
• CAS Number: 357336-20-0
• Molecular Formula: C₁₁H₂₀N₂O₂
• Molecular Weight: 212.29
• Purity: 98%
• Synonyms: (αS,4R)-α-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide; UCB 34714
• Target: SV2A
• Target Protein: Q7L0J3
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IUPAC Name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide
• InChI: InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1
• InChIKey: MSYKRHVOOPPJKU-BDAKNGLRSA-N
• SMILES: CCC[C@@H]1CC(=O)N(C1)[C@@H](CC)C(=O)N

Brivaracetam(Cat No.:R020192) is an anticonvulsant medication used primarily to treat partial-onset seizures in patients with epilepsy. It is a high-affinity ligand for the synaptic vesicle protein 2A (SV2A), a protein involved in neurotransmitter release in the brain. By binding to SV2A, Brivaracetam modulates synaptic transmission, thereby reducing the frequency and severity of seizures. It is a derivative of Levetiracetam, but with greater selectivity and potency, leading to improved efficacy and tolerability for some patients. Brivaracetam is available in various formulations, including oral tablets, oral solution, and intravenous injection, making it versatile in clinical settings. Its favorable pharmacokinetic profile and minimal drug-drug interactions make it a valuable option in epilepsy management.